Ernexa Therapeutics Inc. Total Liabilities and Equity
Ernexa Therapeutics Inc. (ERNA) had Total Liabilities and Equity of $6.32 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-06
- 2026-06-30: Liabilities and Equity $6.32M.
- 2026-03-31: Liabilities and Equity $10.54M.
- 2025-12-31: Liabilities and Equity $5.83M.
- 2025-09-30: Liabilities and Equity $6.17M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $6.32M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $10.54M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $5.83M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $6.17M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $7.58M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $5.06M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $5.27M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $7.72M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $46.49M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $49.66M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $49.13M 10-K · filed 2025-03-12 | |
| 2023-09-30 | $52.25M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $46.95M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $15.11M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $22.28M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $20.93M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $26.90M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $35.38M 10-Q · filed 2022-07-01 | |
| 2021-12-31 | $31.52M 10-K · filed 2023-03-20 | $32.43M 10-K · filed 2022-04-15 |
| 2021-09-30 | $39.39M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $64.71M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $20.70M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $12.91M 10-K/A · filed 2022-07-01 | $3.75M 10-K · filed 2021-03-11 |
| 2020-09-30 | $5.05M 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $6.79M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $11.01M 10-Q · filed 2020-05-20 | |
| 2019-12-31 | $14.13M 10-K · filed 2021-03-11 | |
| 2019-09-30 | $14.92M 10-Q · filed 2019-11-01 | |
| 2019-06-30 | $15.64M 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $16.48M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $14.86M 10-K · filed 2020-03-19 | |
| 2018-09-30 | $15.54M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $16.36M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $15.70M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $16.57M 10-K · filed 2019-03-22 | |
| 2017-09-30 | $17.56M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $18.53M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $17.53M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $16.70M 10-K · filed 2018-03-09 | |
| 2016-09-30 | $14.40M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $14.96M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $16.32M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $16.41M 10-K · filed 2017-03-09 | |
| 2015-09-30 | $17.28M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $17.24M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $20.16M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $22.27M 10-K · filed 2016-03-15 | |
| 2014-09-30 | $22.57M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $22.58M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $15.52M 10-Q · filed 2014-05-15 | |
| 2013-12-31 | $15.46M 10-K · filed 2015-03-27 | |
| 2013-09-30 | $11.65M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $11.38M 10-Q · filed 2013-08-14 | |
| 2013-03-31 | $11.83M 10-Q · filed 2013-05-13 | |
| 2012-12-31 | $12.66M 10-K · filed 2014-03-31 | |
| 2012-09-30 | $12.63M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $12.27M 10-Q · filed 2012-08-14 | |
| 2012-03-31 | $13.11M 10-Q · filed 2012-05-11 | |
| 2011-12-31 | $11.65M 10-K · filed 2013-03-29 | |
| 2011-09-30 | $12.20M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $12.87M 10-Q · filed 2011-08-12 | |
| 2010-12-31 | $13.13M 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |